Pharmacogenomic Information on Ado-Trastuzumab Emtansine

Pharmacogenomic Information

DrugTherapeutic Area*BiomarkerReferenced
Subgroup ‡
Labeling Sections
Ado-Trastuzumab EmtansineOncologyERBB2HER2 protein overexpression or
gene amplification positive
Indications and Usage
Warnings and Precautions
Adverse Reactions
Clinical Pharmacology
Clinical Studies 


* Therapeutic areas do not necessarily reflect the CDER review division.
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.
‡ Common terminology listed based on available data with labeling language in parentheses.


back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 04/20/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.